| 0.387 0.01 (2.73%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.51 |
1-year : | 0.6 |
| Resists | First : | 0.44 |
Second : | 0.51 |
| Pivot price | 0.35 |
|||
| Supports | First : | 0.35 |
Second : | 0.3 |
| MAs | MA(5) : | 0.37 |
MA(20) : | 0.36  |
| MA(100) : | 0.67 |
MA(250) : | 1.52 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 67.4 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 3.32 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACXP ] has closed below upper band by 19.0%. Bollinger Bands are 70.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.4 - 0.4 | 0.4 - 0.4 |
| Low: | 0.37 - 0.38 | 0.38 - 0.38 |
| Close: | 0.38 - 0.39 | 0.39 - 0.39 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Thu, 17 Apr 2025
Acurx Expands Global Patent Portfolio: Phase 3-Ready Drug Targets MRSA, Anthrax, and Superbugs - Stock Titan
Wed, 16 Apr 2025
Press Release Distribution & PR Platform - ACCESS Newswire
Tue, 08 Apr 2025
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Wed, 02 Apr 2025
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 - Yahoo Finance
Fri, 21 Mar 2025
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Tue, 18 Mar 2025
Acurx Pharmaceuticals Reports 2024 Results and Advances Trials - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 424 (K) |
| Shares Short P.Month | 213 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -152.5 % |
| Return on Equity (ttm) | -534.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.45 |
| PEG Ratio | 0 |
| Price to Book value | 9.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|